Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248396 | 0.82 | TACR1 (0.57) | TACR1P2RX7ERCC1ERCC4MEN1 | |
| SCHEMBL17513342 | 0.81 | TACR1 (0.59) | TACR1P2RX7ERCC1ERCC4MEN1 | |
| SCHEMBL7932170 | 0.81 | KMT2A (0.66) | ERCC1ERCC4MEN1KMT2ANPC1 | |
| SCHEMBL8310876 | 0.81 | TACR1 (0.55) | TACR1P2RX7ERCC1ERCC4MEN1 | |
| SCHEMBL17513378 | 0.78 | TACR1 (0.56) | TACR1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL11121464 | 0.78 | TACR1 (0.56) | TACR1P2RX7MEN1KMT2AWDR5 | |
| SCHEMBL23135792 | 0.77 | P2RX7 (0.52) | TACR1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL7937579 | 0.77 | TSHR (0.63) | P2RX7MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL626342 | 0.76 | CYP2C9 (0.66) | TACR1P2RX7MEN1KMT2AWDR5 | |
| SCHEMBL4068730 | 0.76 | TACR1 (0.50) | TACR1P2RX7MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | TACR1 2477/4885P2RX7 3628/4885ERCC1 2534/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | TACR1 146/4885P2RX7 969/4885ERCC1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.